NCT02673736终止1 期
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)
Plexxikon3 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2016年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 11
- 试验地点
- 3
- 主要终点
- Safety of PLX73086, as measured by adverse events and serious adverse events [Part 1 and Part 2 of research study]
研究概览
简要总结
The purpose of this research study is to evaluate safety, pharmacokinetics and preliminary efficacy of the investigational drug PLX73086 in subjects with solid tumors including subjects with locally advanced or refractory tenosynovial giant cell tumor (TGCT).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old.
- •Part 1: Subjects with solid tumors that are refractory to, relapsed after or intolerant to standard therapy, or for whom no standard therapy exists or who are considered by the investigator to be inappropriate for standard therapy.
- •Part 2: Subjects with histologically confirmed, locally advanced or refractory TGCT (including metastatic disease) that has been deemed unresectable by an orthopedic surgeon or similar qualified personnel.
- •Measurable disease by RECIST 1.1 criteria.
- •Women of child-bearing potential must have a negative pregnancy test within 7 days prior to initiation of dosing and must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 3 months after the last dose of study drug, Fertile men must also agree to use an acceptable method of birth control while on study drug and up to 3 months after the last dose of study drug.
- •All associated toxicity from previous or concurrent cancer therapy must be resolved (to ≤ Grade 1 or Baseline) prior to study treatment administration.
- •Willingness and ability to provide written informed consent prior to any study-related procedures and comply with all study requirements.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-
- •Life expectancy ≥ 3 months.
- •Adequate hematologic, hepatic, and renal function.
排除标准
- •Symptomatic brain metastases.
- •Investigational drug use within 14 days (or 5 half-lives, whichever is longer) of the first dose of PLX
- •Major surgical procedure, open biopsy (excluding skin cancer resection), or significant traumatic injury within 14 days of initiating study drug (unless the wound has healed) or anticipation of the need for major surgery during the study.
- •Active secondary malignancy unless the malignancy is not expected to interfere with the evaluation of safety and is approved by the Medical Monitor. Examples of the latter include basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, and isolated elevation of prostate-specific antigen. Subjects with a completely treated prior malignancy and no evidence of disease for ≥ 2 years are eligible.
- •Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption.
- •Baseline mean QTcF ≥ 450 msec (for males) or ≥ 470 msec (for females) at Screening.
- •Clinically significant cardiac arrhythmias including bradyarrhythmias and/or subjects who require anti-arrhythmic therapy (excluding beta blockers or digoxin). Subjects with controlled atrial fibrillation are not excluded
- •Congenital long QT syndrome or subjects taking concomitant medications known to prolong the QT interval (e.g., tricyclics, azithromycin, methadone).
- •History of clinically significant cardiac disease or congestive heart failure > New York Heart Association (NYHA) class
- •Subjects must not have unstable angina (anginal symptoms at rest) or new-onset angina within the last 3 months or myocardial infarction within the past 6 months.
- •Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than 1 month before the start of study medication).
- •Strong CYP3A4 inhibitors or inducers as well as inhibitors of breast cancer resistance protein (BCRP) within 14 days or 5 drug half-lives, whichever is longer, before start of study drug.
- •Subjects with > Grade 1 (high or low) serum potassium, magnesium, or calcium levels.
- •Women who are breast-feeding or pregnant.
- •Non-healing wound, ulcer, or bone fracture.
- •Known HIV-positive individuals on combination antiretroviral therapy.
- •Subjects with known active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy.
- •Uncontrolled intercurrent illness (i.e., active infection ≥ Grade 2) or concurrent condition that, in the opinion of the Investigator, would interfere with the study endpoints or the subject's ability to participate.
- •The presence of a medical or psychiatric condition that, in the opinion of the Principal Investigator, makes the subject inappropriate for inclusion in this study.
研究组 & 干预措施
PLX73086
Experimental
Part 1: Open-label, sequential PLX73086 dose escalation in approximately 36 solid tumors subjects.
Part 2: Extension cohort at the recommended phase 2 dose (RP2D) of PLX73086 in approximately 30 subjects with histologically confirmed, unresectable, locally advanced or refractory TGCT (including metastatic disease).
干预措施: PLX73086 (Drug)
结局指标
主要结局
Safety of PLX73086, as measured by adverse events and serious adverse events [Part 1 and Part 2 of research study]
时间窗: 1 year
Area under the concentration-time curve (AUC) of PLX73086 [Part 1 of research study]
时间窗: 1 year
Maximum observed concentration (Cmax) of PLX73086 [Part 1 of research study]
时间窗: 1 year
Half life (t1/2) of PLX73086 [Part 1 of research study]
时间窗: 1 year
Time to peak concentration (Tmax) of PLX73086 [Part 1 of research study]
时间窗: 1 year
次要结局
- Efficacy of PLX73086 measured by overall response rate (ORR) [Part 1 of research study](1 year)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVGHivHSVNCT03762772CONRAD16
进行中（未招募）
1 期
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)Hematological MalignanciesNCT05347225Merck Sharp & Dohme LLC12
Unknown
1 期
GR1405 Injection in Patients With Advanced Solid Tumor or LymphomaTumor, SolidLymphomaNCT03731390Chinese Academy of Medical Sciences30
招募中
1 期
BC008-1A Injection for Recurrent CNS WHO G4 GliomaGlioma Tumor RecurrenceGlioma, Recurrent High GradeGlioblastomas (GBM)Glioblastoma WHO Grade IVGliomaNCT06773481Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.40
尚未招募
1 期
Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant TumorsAdvanced Malignant TumorsNCT05728541CSPC Ouyi Pharmaceutical Co., Ltd.367